BU AMYLOIDOSIS CENTER

BU AMYLOIDOSIS CENTER

@BU_Amyloidosis

Followers1.2K
Following58

Official Twitter for the Amyloidosis Center at Boston University Medical Campus. Recognized as a leader in basic and clinical research on Amyloidosis.

Boston, MA
Joined on February 22, 2017
@BU_Amyloidosis Statistics

We looked inside some of the tweets by @BU_Amyloidosis and found useful information for you.

Inside 100 Tweets

Time between tweets:
2 days
Average replies
0
Average retweets
4
Average likes
14
Tweets with photos
29 / 100
Tweets with videos
0 / 100
Tweets with links
0 / 100
Fun Fact

The average Twitter user has 126 followers.

Working Together to Cure Amyloidosis! 

Donate today to support The Amyloidosis Center on #GivingTuesday, December 3, 2019.
#AmyloidResearchFund

Your contribution matters no matter how small or big! #InItToWinIt

#SUPPORT #WildflowerFoundationMatch

Working Together to Cure Amyloidosis! Donate today to support The Amyloidosis Center on #GivingTuesday, December 3, 2019. #AmyloidResearchFund Your contribution matters no matter how small or big! #InItToWinIt #SUPPORT #WildflowerFoundationMatch

@BU_Amyloidosis Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II Study

0
3
6
We have an opening for July 1, 2020 for our 1-year cardiac #amyloidosis research fellowship at the BU/BMC Amyloidosis Center @BU_Amyloidosis. Any MD trained physician who has completed IM training is eligible. Details attached. Email with questions.

We have an opening for July 1, 2020 for our 1-year cardiac #amyloidosis research fellowship at the BU/BMC Amyloidosis Center @BU_Amyloidosis. Any MD trained physician who has completed IM training is eligible. Details attached. Email with questions.

Quoted @frederickruberg

We have an opening for July 1, 2020 for our 1-year cardiac #amyloidosis research fellowship at the BU/BMC Amyloidosis Center @BU_Amyloidosis. Any MD trained physician who has completed IM training is eligible. Details attached. Email with questions.

We have an opening for July 1, 2020 for our 1-year cardiac #amyloidosis research fellowship at the BU/BMC Amyloidosis Center @BU_Amyloidosis. Any MD trained physician who has completed IM training is eligible. Details attached. Email with questions.

#medtwitter #cardiotwitter see below for an exciting research fellowship opportunity @BU_Amyloidosis and @BUcards with an amazing mentor!

The Commonwealth of Massachusetts proclaims February 6, 2020 to be CARDIAC AMYLOIDOSIS RECOGNITION DAY. 

We are thankful to Governor Charles Baker of the commonwealth for this proclamation.

The Commonwealth of Massachusetts proclaims February 6, 2020 to be CARDIAC AMYLOIDOSIS RECOGNITION DAY. We are thankful to Governor Charles Baker of the commonwealth for this proclamation.

Our Director Dr. Vaishali Sanchorawala talks about AL Amyloidosis in the "Daratumumab Safe And Effective Option For Treating Light Chain (AL) Amyloidosis" article published today February 4, 2020. Read more in the link above.

0
0
2

Daratumumab safe and effective option for treating light chain (AL) amyloidosis

1
3
14

Daratumumab proves to be effective in AL amyloidosis in a clinical trial led by our director @vsanchorawala, published online in @BloodJournal https://www.ncbi.nlm.nih.gov/pubmed/31978210 

0
5
16

Phase 2 data on daratumamab for AL amyloidosis from @vsanchorawala and colleagues @BU_Amyloidosis - good responses, well tolerated. https://doi.org/10.1182/blood.2019004436 …

1
5
20

Incredible work from my colleagues! @BU_Amyloidosis @vsanchorawala @Jmarksloan Continung to expand rx for AL amyloidosis 👏🏼 Safety, Tolerability, and Response Rates of Daratumumab in Relapsed AL Amyloidosis: Results of a Phase II Study | https://ashpublications.org/blood/article/doi/10.1182/blood.2019004436/440750/Safety-Tolerability-and-Response-Rates-of#.XjEDq30zBYg.twitter …

0
2
16

36 days left for the International Amyloidosis Symposium in Tarragona, Spain! #ISA2020 We @BU_Amyloidosis are getting excited to participate and present, collaborate and make new alliances. https://www.isa2020.org/  Join us at this exciting meeting.

1
2
8

2020 to a good start -- one manuscript accepted in Blood @BloodJournal and one in Blood Advances @BloodAdvances!

1
1
46

Replying to @MayoAmyloid @RahmaWarsameMD

Similar to results from @BU_Amyloidosis of 125 patients treated with IMiD on 3 different clinical trials, pooled analysis. With a median follow‐up of 8.4 years, Median OS is 4.3 years and median PFS is 2.1 years. https://www.ncbi.nlm.nih.gov/pubmed/31020691 

0
1
7

Hey #MedTwitter, please welcome my mentor @frederickruberg from @BUcards and @BU_Amyloidosis! So happy that Rick is finally on here!

1
4
32

Highlight of the day were the hands on breakout sessions with Lisa Mendelson, NP; David Hughes, PharmD and Mathew Maurer, MD.

0
0
4

We at @BU_Amyloidosis center participated and directed the Masterclass of “The art and science of managing amyloidosis” in partnership with @Amyloidosis_ARC and @BU_CME on January 10, 2020 in Dallas, Tx.

1
0
14

"Carpal tunnel patients with positive tissue for amyloidosis must be worked up for AL amyloidosis. Don't assume ATTR" #ARCmasterclass @MathewMaurer @maz_hanna @vsanchorawala

0
3
13
⁦@lis589⁩ presented the challenges of the great imitator. #amyloidosis #ARCmasterclass

@lis589⁩ presented the challenges of the great imitator. #amyloidosis #ARCmasterclass

#ARCMasterClass 'There're somethings they don't teach you in medschool.'

#ARCMasterClass 'There're somethings they don't teach you in medschool.'

Calling all neurologists! Amyloid neuropathy is progressive unlike diabetic neuropathy. Genetic testing is free and
FDA approved therapies are available for hATTR

Calling all neurologists! Amyloid neuropathy is progressive unlike diabetic neuropathy. Genetic testing is free and FDA approved therapies are available for hATTR

Next Page